INTRODUCTION
Serum from most patients with systemic lupus erythematosus (SLE) 1 contain immunoglobulins whose antiReceived for publication 15 July 1975 and in revised form 16 October 1975. 'Abbreviations used in this paper: B, bone marrow derived; CC5o, loga of the reciprocal of the greatest serum dilution killing 50%o of normal human peripheral blood lymphocytes; CNS, central nervous system; FCS, fetal calf serum; HBSS, Hank's balanced salt solution; NHS, normal human serum; PBL, peripheral blood lymphocytes; SLE, systemic lupus erythematosus; T, thymus derived. body activity is directed at heterologous and autologous lymphocytes. Several methods have been used to detect these antibodies including immunofluorescence (1, 2) , lymphocytotoxicity, (3) (4) (5) , and suppression of in vitro lymphocyte function (6) (7) (8) (9) . Of these antilymphocyte factors, complement-dependent IgM lymphocytotoxic antibodies have been most thoroughly investigated. The antigenic determinants on the lymphocyte surface with which the cytotoxic antibody reacts have not yet been defined. A comparison of the cytotoxicity of SLE serum to lymphocytes from healthy individuals and patients with chronic lymphocytic leukemia led Lies et al. (10) to conclude that the antibodies were relatively T-(thymus-derived) cell specific. More recently, however, Winfield et al. (11) have shown that SLE sera are cytotoxic to both T-and B-(bone marrow-derived) cells purified from the peripheral blood of normal individuals. Thus, it seems possible that SLE sera contain varying amounts of antibody directed at T-or B-cell determinants and that the observed specificity of any individual serum depends on the relative proportion of those antibody populations.
Since, in mice, it has been shown that there are shared antigenic determinants between T cells and brain tissue (12) , we have attempted to separate anti-Tfrom anti-B-cell antibodies by absorption of SLE serum with human brain tissue. We found that human brain removed most, but not all, of the lymphocytotoxic activity. A portion of the absorbed antibody could be eluted from the brain. Brain absorption, however, did not separate the antibodies according to T-or B-cell specificity. The cytotoxic antibodies in the unabsorbed SLE sera, in the brain-absorbed sera, and in the eluates from the brain absorbents reacted equally against B and T lymphocytes. A comparison of serum cytotoxic capacity with specific systemic manifestations of SLE reveals that central nervous system (CNS) disease is associated with increased lymphocytotoxicity. This observation suggests a possible pathogenic role for the circulating brain-reactive antibodies.
METHODS
Clinical material. Sera were obtained from 40 randomly chosen patients with SLE, all of whom fulfilled the preliminary diagnostic criteria of the American Rheumatism Association (13) . Sera from six patients were studied in detail. Four of the six were selected for study because they were strongly cytotoxic, each having a 50%o lymphocytotoxicity titer of 1: 64 or greater (CC5o greater than 6). The other two patients' sera were relatively weakly cytotoxic, each with 50% cytotoxicity titers of 1: 2. A pool of normal human sera (NHS) comprised of a mixture of unequal amounts of serum from 12 healthy adult donors was used as a control serum source. The sera were stored at -20'C without preservatives. Before use, all sera were heated at 56'C for 45 min.
The pI of 40%o formaldehyde adjusted to pH 7.0. 100 cells were examined in each well, and the number of cells stained with eosin enumerated. The mean percentage of dead cells in the triplicate assays was expressed as percent cytotoxicity. The 50% cytotoxicity titer (CC5o), that is, the log2 of the reciprocal of the greatest serum dilution producing 50% cytotoxicity, provided a measure of the relative cytotoxic capacity of each serum.
Absorptions. Tissue from the frontal cortex of human brains known to be free of pathology were obtained at postmortem examination within 24 h after death. After removal of the meninges and surface blood vessels, the tissue was finely diced with a scalpel and then homogenized by hand in a ground glass TenBroeck homogenizer. The homogenate from each gram of tissue was suspended in 5 ml of HBSS and washed four times by 2,000 g centrifugation at 4°C for 15 min. For each absorption the packed homogenate was resuspended in an equal volume of serum at 4VC for 1 h. The absorbed serum supernate was removed after centrifugation of the suspension at 2,000 g for 15 min at 4VC. Absorptions with a liver homogenate prepared in the same fashion as the brain homogenate and absorptions with human erythrocytes were also done at a 1: 1 ratio of the volume of packed cells to serum volume.
Elutions. After removal of the serum supernate, the pelleted brain homogenate used for the first serum absorption was washed four times by centrifugation in 5 vol of 0.01 M phosphate buffer, pH 7.4 in 0.15 M NaCl (phosphate-buffered saline) maintained at 4°C. The pelleted homogenate was then resuspended in an equal volume of phosphatebuffered saline and incubated at 37'C for 45 min. After centrifugation the supernatant brain eluate was removed.
Lymphocyte fractionation. Normal human peripheral blood lymphocytes (PBL) were fractionated into T and B cell-rich populations by fractionation on columns of nylon wool (Leuko-Pak, Travenol Laboratories, Deerfield, Ill.). T cells were obtained as previously described (15) . Usually 50 X 108 PBL in 1 ml were applied to columns containing 600 mg of nylon wool. After incubation at 37°C for 45 min, the nonadherent cells were removed by the dropwise application of 25 ml of medium. About 20-30 X 10. lymphocytes were recovered in the eluate. There were greater than 85% erythrocyte-rosetting cells and less than 5% surface immunoglobulin-bearing cells (detectable by direct immunofluorescence) in that T cell-rich population. After washing the column with an additional 100 ml of medium, the nylon wool was compressed to the bottom of the column and the wash discarded. Fresh medium (8 ml) was added to the columns and the nylon wool then agitated up and down through the medium about five times. The medium was drained with recompression of the wool, another 8 ml of medium was added, and the agitation procedure repeated. When combined, the two 8-ml effluents contained 2-4 X 10' lymphocytes, of which more than 80% had surface immunoglobulin and less than 5% were erythrocyte rosetting. This B-cell population and the previously obtained T cells were centrifuged at 190 g for 10 min at 4VC and resuspended at a concentration of 10' cells/ml for use in the cytotoxicity assay.
RESULTS
Absorption with brain tissue effectively diminished the lymphocytotoxic activity of serum from all six patients with SLE. The results obtained after absorption of three of the more potently lymphocytotoxic sera are shown in Fig. 1 . Absorption of a fourth strongly cytotoxic serum, CH (not shown in the figure), produced results essentially identical to serum AF. Before absorption, sera AF, JH, and CH each had a 50% lymphocytotoxicity titer of 1: 128 and serum AO had a titer of 1: 64. Each of the initial brain absorptions lowered the percent cytotoxicity obtained. After three absorptions all four sera produced 50% lymphocytotoxicity at a 1: 4 dilution. Thus, three absorptions with brain tissue remove more than 90% of the lymphocytotoxic activity from these sera. The cytotoxicity of sera AO, AF, and CH was not further diminished by additional absorptions. A fourth absorption of serum JH, however, lead to further depletion of its cytotoxicity, reducing it to below 30%. Brain absorption completely removed lym- NUMBER OF ABSORPTIONS FIGURE 1 The effect of human brain tissue absorption on the lymphocytotoxicity in SLE sera. The residual percent cytotoxicity in a 1: 2 dilution of SLE sera AF, AO, and JH after absorption with equal volumes of homogenized brain is presented as a function of the number of brain absorptions. The cytotoxicity in a similarly absorbed NHS is presented for comparison.
phocytotoxic activity from two weakly cytotoxic sera. Sera LF and AH, both killing 50% of normal human lymphocytes at a 1: 2 dilution, exhibited less than 10% cytotoxicity after two brain absorptions. There is little change in the lymphocytotoxic activity of the pooled NHS after three brain absorptions, but after the fourth absorption there is a consistent increase to greater than 20% cytotoxicity (Fig. 1) . The percent cytotoxicities obtained after four brain absorptions of serum JH and the NHS pool are not significantly different. Absorption with brain tissue, then, removes most of the lymphocytotoxicity from all of the lupus sera tested, but some of the sera contain lymphocytotoxic activity that is not brain reactive.
The brain antigens with which the lymphocytotoxic antibodies combine are not present on rodent brain. A comparison of the effects of four absorptions of serum JH with human or mouse brain homogenates is presented in Table I . Absorption with human brain tissue removes nearly all of the cytotoxic activity while identical absorptions with mouse brain have virtually no effect. Rat brain has also been tested and it, too, is unable to remove significant amounts of lymphocytotoxicity from SLE sera. Thus, the reactivity of lymphocytotoxic antibody with human brain is not the result of nonspecific binding to mammalian cerebral tissue.
The ability of other nonlymphoid tissues of human origin to deplete lymphocytotoxic activity from SLE sera has been examined. The effects of absorptions of serum JH with erythrocytes, liver, and brain tissue are presented in Fig. 2 . Multiple absorptions with equal volumes of packed erythrocytes had no effect on the cytotoxic capacity. Three other sera were similarly absorbed and they, too, were completely unaffected. In each case the erythrocytes used for absorption were Lymphocytotoxic activity is recoverable from the brain tissue absorbents by elution at 37°C. The eluates from brain tissue used to absorb SLE sera with high lymphocytotoxic capacity (sera AF, AO, and JH) are themselves highly cytotoxic (Table II) . In contrast, the eluates from brain tissue used to absorb NHS are not significantly cytotoxic. Further, there is minimal lymphocytotoxic activity in the eluates from brain tissue used to absorb the weakly cytotoxic serum from LF, a patient with SLE. It appears, therefore, that the amount of lymphocytotoxicity in the brain eluate is proportional to the cytotoxic capacity of the serum from which it was derived.
To define the character of the lymphocytotoxic factor in the brain eluates, we examined the effects of treating the eluates with rabbit antisera to human immunoglobulins. Eluate AO, when mixed with an equal volume of normal rabbit serum, produces a mean cytotoxicity of 74% (Table III) . Mixing that eluate with rabbit serum containing antibodies specific for human IgG (anti-v-chain) does not significantly alter the cytotoxicity. The lymphocytotoxic activity is completely eliminated, however, by the addition of antihuman IgM (is-chain specific). The rabbit sera themselves are not cytotoxic to the lymphocytes as shown in the control experiments using eluates from brain tissue used to absorb NHS. Elimination of the lymphocytotoxicity of I The data are expressed as the mean 50% cytotoxicity titer (CC50) zSE. § Difference between involved and uninvolved statistically significant P < 0.02. All other comparisons P > 0.2. Students t test was used with the P value based on two-tail analysis.
the difference is not statistically significant (P > 0.2).
If that same comparison is limited to the patients who did not have CNS disease, there was no difference between the mean CC60 of those with or without renal disease. Neither the presence of active skin disease nor serositis (pleuritis, pericarditis, or peritonitis) are associated with increased cytotoxic capacity. SLE patients with hematologic abnormalities (hemolytic anemia and/ or thrombocytopenia), however, have a significantly higher serum cytotoxic capacity than do those patients without hematologic involvement. This relationship holds even if the comparison is limited to the 25 patients without CNS disease. Thus, although lymphocytotoxic antibodies are present in the sera of a majority of patients with SLE, the cytotoxic capacity is greater in the sera of those patients with CNS involvement and hematologic abnormalities. The increased cytotoxic capacity can not be attributed solely to the severity of the SLE, since it is not found in association with kidney, skin, or serosal involvement. DISCUSSION Absorption with normal brain tissue from the cerebral cortex removes most of the lymphocytotoxic antibodies from SLE sera. In every case studied, brain absorption eliminated greater than 90% of the cytotoxic capacity. Absorption of three of six SLE sera reduced the cytotoxic capacity to the same level as a similarly absorbed noncytotoxic NHS, indicating that the brain tissue may have removed all of the lymphocytotoxic antibodies from those sera. The other three sera, however, retained residual lymphocytotoxicity that could not be removed with additional brain absorptions. Most lymphocytotoxic antibodies, therefore, are directed at anti-genic determinants that are found both on lymphocytes and central nervous tissue. A subset of antilymphocyte antibodies, however, react with antigenic determinants that lymphocytes do not share with the brain.
Cross-reactivity between lymphocytes and brain antigens has been extensively studied in mice. Antibodies directed at the 0-marker, an alloantigen present on T lymphocytes, cross-react with mouse brain (12) . In addition, heterologous antisera produced against mouse brain contain lymphocytotoxic antibodies specific for T cells (16) . The naturally occurring thymocytotoxic antibody that increases with age in NZB mice is relatively T-cell specific, and this, too, cross-reacts with mouse brain antigens (17) (18) (19) (24) .
Circulating brain-reactive antibodies may be responsible for some forms of SLE-CNS disease. Antibodies to lymphocyte membrane constituents can interfere with cell function in vitro (6) (7) (8) (9) . The mechanism of this suppression has not been elucidated. Antibodies may block access to specific lymphocyte receptors. Alternatively, they may impair membrane dynamics. In guinea pigs, for instance, suppression of immune response genecontrolled antigen stimulation by alloantisera appears to be the result of an alteration of the cell membrane that prevents the lymphocyte from responding to the presence of the antigen in its receptor (25 The cytotoxic capacity is higher in the sera from patients with CNS involvement than it is in the sera of other SLE patients. This difference cannot be attributed solely to greater disease activity in the former group since a similar comparison of those with and without renal disease reveals no significant difference. In fact, of the several manifestations of SLE examined, other than CNS disease, only the presence of a hematologic abnormality (thrombocytopenia or hemolytic anemia) is associated with significantly higher serum lymphocytotoxicity. This latter association may reflect a common mechanism for the induction of autoantibodies against a number of blood constituents. Recent studies in mice have demonstrated that, in addition to antibodies to lymphocytes, heterologous antibrain sera also contain antibodies directed at the stem cell precursors of erythrocytes, platelets, and neutrophils (26). Butler et al. (27) have previously reported that SLE patients with CNS disease and hematologic abnormalities were more like to have circulating lymphocytotoxic antibody than were other SLE patients.
The association of CNS disease with high titer lymphocytotoxic antibody is based on a retrospective analysis of the clinical records of patients whose sera we had previously tested for cytotoxic capacity. Although there was no conscious selection of serum samples, we recognize that this process may have introduced an inapparent bias. In the absence of any obvious bias however, these results should stimulate further investigation into the role of lymphocyte-directed antibody in the development of the CNS manifestations of SLE.
